In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M.
Since then, several news stories have reported promising developments for ONC201. Check out the coverage:
- The Philadelphia Inquirer: “Cancer therapy shows promise for some brain tumors”
- Atrium Health: “Finding hope in the face of brain cancer: After being diagnosed with a brain tumor, Amanda’s future was uncertain. But participating in a Phase 2 clinical trial has given her more time, more hope and a new mission.” (Also covered on WSOC-TV)
- Michigan Medicine: “Brain cancer patient finds hope with emerging new therapy”
- Omaha World-Herald: “Experimental drug ‘nothing short of miraculous’ for father of 4 with super-rare brain tumor”
To learn more about our ONC201 project, click here.